Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

multi-antigen-directed autologous T cells NEXI-002

A preparation of autologous T cells targeting several multiple myeloma (MM)-associated antigens, with potential immunomodulating and antineoplastic activities. Peripheral blood mononuclear cells (PBMC) from the patient are collected and ex vivo exposed to nanoparticles that mimic antigen-presenting cells (APCs) loaded with multiple MM-associated antigens, including Wilms' tumor 1 (WT1), CD138 (syndecan-1; SDC1), cancer-testis antigen NY-ESO-1 and CS1 (CD319; CRACC; SLAMF7), and are further enriched and expanded ex-vivo before being re-introduced into the patient. Upon administration, the multi-antigen-directed autologous T cells NEXI-002 are re-introduced into the patient, where they target and kill tumor cells expressing these antigens.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous MM-associated antigens specific T cells NEXI-002
NEXI-002 T cells
TAA primed antigen-specific CD8+ T cells NEXI-002
Code name:NEXI 002
NEXI002
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search